Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke
NCT ID: NCT01623622
Last Updated: 2017-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
270 participants
INTERVENTIONAL
2012-07-31
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of Mongolian Medicine ZhenBao Pills for Upper-limb Dysfunction After Stroke
NCT06049498
Clinical Plan of Ischemic Stroke
NCT04953663
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
NCT03296618
Evaluating the Therapeutic Effect of Acupuncture on Acute Ischemic Stroke Patients
NCT02210988
Acupuncture Intervention to Improve Neurological Function and Anti-inflammatory Effect in Acute Ischemic Stroke (ANAIS)
NCT03097055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HC-58 low dose
Low dose
HC-58
once or more / week
HC-58 high dose
High dose
HC-58
once or more / week
Placebo
Placebo
once or more / week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HC-58
once or more / week
Placebo
once or more / week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Within 28 days after stroke at enrollment
Exclusion Criteria
* Patients with pain between shoulder and hand on paralysed side which affects medical rehabilitation
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asahi Kasei Pharma Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toshiya Umeda
Role: STUDY_DIRECTOR
Asahi Kasei Pharma Corporation Clinical Development Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fukui-shi, Fukui, Japan
Hamamatsu, Shizuoka, Japan
Kumamoto, Kumamoto, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HC-58 (SHS) II-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.